Nanoparticles in radiation oncology: From bench-side to bedside
Chloé Rancoule1, Nicolas Magné2, Alexis Vallard1
1Radiotherapy Department, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France.
Cancer Letters
|March 19, 2016
Summary
Nanoparticles (NPs) show promise in enhancing radiation therapy by increasing tumor absorption and delivering drugs. Further research into NP mechanisms, biocompatibility, and toxicity is needed for safe clinical use.
Area of Science:
- Oncology
- Radiotherapy
- Nanomedicine
Background:
- Nanoparticles (NPs) are increasingly studied for their potential to improve cancer radiation therapy.
- Pre-clinical research indicates NPs can act as radiosensitizers and drug delivery vectors.
- NPs also offer theranostic capabilities, serving as contrast agents for imaging.
Purpose of the Study:
- To review the diverse applications of nanoparticles in radiotherapy.
- To discuss the potential clinical integration of NPs in cancer treatment.
- To highlight the challenges and future directions for NP-based radiotherapy.
Main Methods:
- Literature review of preclinical and clinical studies on nanoparticles in radiation therapy.
- Analysis of NP mechanisms, including radiosensitization and drug delivery.
- Evaluation of NP biocompatibility, toxicity, and clearance pathways.
Main Results:
- NPs can enhance radiation absorption in tumors, increasing efficacy and sparing healthy tissue.
- NPs can be engineered as carriers for radiosensitizing drugs, targeting cancer cells.
- NPs offer theranostic potential, combining diagnostic imaging with therapeutic effects.
Conclusions:
- Nanoparticles hold significant promise for advancing radiotherapy through radiosensitization, targeted drug delivery, and theranostics.
- Clinical translation is hindered by the need for better understanding of NP biological mechanisms, biocompatibility, and toxicity.
- Further rigorous investigation is essential to ensure the safe and effective clinical application of NPs in radiation oncology.
